Goodable

In Livingston Texas, coach Heather Mosser started a program that paired her varsity softball athletes with students who have disabilities. They exercised and trained together for months. This is what happened when she brought the students onto the field to throw the opening pitch. Want more videos like this? Follow us on YouTube and Twitter @Goodable. Tap the share button to send this inspiring story to a friend.

In Livingston Texas, coach Heather Mosser started a program that paired her varsity softball athletes with students who have disabilities.
They exercised and trained together for months.
This is what happened when she brought the students onto the field to throw the opening pitch.

WATCH: These Texas High School Softball Players Help Students With Disabilities Throw The Opening Pitch

Good News Network

A Tunisian carmaker is betting the sun can help sell electric vehicles in Africa.

Bako Motors is rolling out two solar-powered EVs in Tunisia, a small delivery vehicle called the B-Van and a two-seater passenger car called the Bee. The company is already manufacturing the models and selling them in showrooms on the continent.

CNN reported the market for EVs in Africa is predicted to reach several billion dollars by the end of the decade. Many countries in Africa import most of their vehicles.

Bako Motors is pitching its cars into a market with a big obstacle for electric transport. Charging infrastructure is largely absent, limiting wider use of EVs. The company’s answer is to use solar panels on the roof of each vehicle.

With those panels, a Bako vehicle can get 50 kilometres of charge per day for free, according to the source text. That extra energy can improve dependability in places without charging points.

“The solar cells provide us with more than 50% of our needs,” Boubaker Siala, founder and CEO of Bako Motors, told CNN.

“For example, the B-Van, for commercial use, you can have free energy for about 50 kilometers per day… 17,000 kilometers (10,563 miles) per year. It’s huge.”

The company says about 40 percent of the material used in each vehicle is sourced from the continent. That includes the lithium-iron-phosphate batteries and steel.

Price is a major part of Bako Motors’ pitch. The B-Van costs about 25,000 Tunisian dinar, or $8,500. The Bee is priced at $6,200.

The vehicles are not built for speed. The source text says the Bee has a top speed lower than many of the continent’s petrol-powered mopeds. But Bako is leaning on lower running costs instead. A day in the sun can charge more than two-thirds of the Bee’s battery, according to the source text, which could mean substantial savings in fuel and electricity.

The B-Van is aimed at commercial users. It can carry 363 kilograms of cargo and has a range of up to 261 kilometres. The source text says it is designed for last-mile delivery and artisanal market businesses.

Bako Motors’ publicity video for the B-Van was shot in Sidi Bou Said, near Carthage, according to the source text. It cites the whitewashed streets there as an example of the kind of setting where artisanal market businesses flourish.

The company has already moved past some of the toughest early steps. The source text says the design work and the construction of manufacturing facilities are complete. Bako Motors now needs its plants in Saudi Arabia and Tunisia to run at nameplate capacity.

Its target is to produce 8,000 vehicles for cities across the continent, with eventual exports to Europe also part of the plan.

Siala says the company sees a large opening in the African market.

“The addressable market in Africa is about 1 million vehicles per year. We have to prepare ourselves for this transition (and) offer affordable and good products for the African citizen,” says Siala. “We are targeting maybe 5 to 10% of this market.”

📸 credit: Bako Motors

Tunisian Solar Cars are Using Africa’s Sun To Add 30 Free Miles A Day

Talker News

A tiny win for a species hanging on by a thread. Healesville Sanctuary in Victoria has successfully bred 12 critically endangered mountain pygmy possums, with fewer than 2,000 of the animals left in the wild.

The sanctuary said three mothers each produced litters of four offspring in its breeding program, the maximum number of young for the species.

The joeys were born last October. They spent four weeks in their mothers' pouches before they were old enough to be left in nest boxes.

Mountain pygmy possums become fully independent at about three months old, but zookeepers have only now had their first in-person look at the joeys during their first vet checks at the sanctuary's Australian Wildlife Health Centre.

Staff had been watching their movements on CCTV before then.

It is understood fewer than 2,000 mountain pygmy possums remain in the wild, and Healesville Sanctuary said every single one is valuable.

Healesville Sanctuary Threatened Species Coordinator Nicole Boys said the joeys already resembled the adults.

“The best way to identify them is by their big heads and much littler bodies.”

She said the 12 young possums would stay at the sanctuary as part of the breeding program.

“These little joeys will remain here in our breeding programme, and hopefully, in the coming years they will go on to breed, sharing their genes.”

The species is critically endangered because its alpine habitat is shrinking due to climate change. Its key food source, the Bogong Moth, has also significantly declined in recent years.

The animals also face habitat fragmentation and predation from cats and foxes.

Only 2,000 Left, And Now 12 More: Tiny Possums Are Getting a Lifeline

Mongabay

For more than 50 years, ariel toucans have been back in Rio de Janeiro’s Tijuca National Park. A new study suggests they have also returned to the job they once did there, eating and dispersing seeds from a wide range of native plants in the forest.

The study found the ariel toucan, Ramphastos ariel, has almost entirely settled back into its original ecological role in Tijuca, which the source text describes as the world’s largest urban forest in southeastern Brazil. The bird had become locally extinct in the 1960s.

Researchers followed ariel toucans through the Tijuca forest for a full year and recorded every plant species the birds ate. They compared those observations with a list of 101 native plant species that the toucan had historically interacted with.

The team often walked more than 20 kilometers a day through the forest to observe the birds’ diet. They found the toucans interacted with at least 76 percent of the plants historically on the species’ menu.

Lead author Flávia Zagury, an urban ecology researcher at the Federal University of Rio de Janeiro, described the birds’ feeding skills in comments to Mongabay.

“They are such sociable and intelligent beings. The way they are able to handle fruits: Sometimes it has a hard capsule on the outside, and they hold it with their little feet and open it with their beaks,” Zagury told Mongabay by phone. “They have an incredible ability to access these resources.”

The study also found the birds were feeding on fruits and seeds from plants that few other animals can crack open. That may make them important dispersers for endangered trees, including the jussara palm, Euterpe edulis, and the bicuíba-branca, Virola bicuhyba.

The source text says both tree species are native, nationally classified as endangered, and have lost more than half of their range.

“The jussara palm, a species in danger of extinction, was one of its favorites. I think it was the champion, the one it ate the most,” Zagury said.

Researchers also looked at how the toucans fit alongside other animals that have recently been reintroduced to the park, including red-rumped agoutis, Dasyprocta leporina, and brown howler monkeys, Alouatta guariba.

They found minimal dietary overlap between those species and the toucans. According to the source text, that points to a “functional uniqueness” for the birds in the park’s ecosystem, especially when it comes to plants with larger seeds, Zagury added.

While the toucans interacted with 76 percent of the full plant list, the figure rose for plants with medium and large seeds. The study found the birds interacted with nearly 90 percent of the plants in that group, defined in the source text as seeds larger than 6 millimeters.

The ariel toucan was reintroduced to Tijuca in 1970. Primatologist Adelmar Coimbra Filho released 46 individuals inside the park as part of an effort to restore fauna in the degraded forest.

Since then, the released birds had been left largely unmonitored, according to the source text. The new study is among the first to assess that reintroduction more than half a century later.

Even with the new findings, Zagury said there are still major gaps in what researchers know about the birds’ effects on the forest.

A lot remains unknown, including how much ariel toucans contribute to the dispersal of different plant species and to reforestation, she said.

“It’s pretty much a blank canvas; there is so much we still don’t know,” Zagury added.

"Ramphastos vitellinus ariel" by Guilherme Thielen is licensed under CC BY 4.0. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/?ref=openverse.

After 50 Years, Toucans are Returning to Rio and Reviving a Lost Forest Role

Science Alert

Peanut shells usually end up as a low-value byproduct. A team of Australian researchers says they can do much more, turning that waste into graphene-like carbon materials with a process that uses less energy and no chemicals.

Worldwide peanut production creates more than 10 million tons of discarded shells each year, according to the research. The new study, led by the University of New South Wales in Australia, found the shells have the potential to help make graphene in a cheaper and more environmentally friendly way than some conventional production methods.

Graphene is made from carbon and is often described as a “wonder” material because it is very strong, very light, and conducts heat and electricity well. It is already widely used and is expected to improve consumer electronics in the future.

But graphene is also hard to produce at scale and expensive to make. The researchers say alternative manufacturing methods could improve energy systems, data storage and other modern technologies.

UNSW mechanical engineer Guan Yeoh said peanut shells are an overlooked source material.

“Most of the waste from the shell is either discarded or recycled into low-value applications that don't maximize their full potential,” he said.

“What we have shown in this work is that basic peanut shells can be turned into high-quality graphene, using much lower energy than is currently required and therefore at a lower cost. We also do not need to use any chemicals, so there is an added environmental benefit.”

A key part of the process is lignin, a natural polymer found in most plants that contains a lot of carbon. Peanut shells already contain lignin, but the researchers needed to work out the best way to prepare the shells before turning them into graphene.

The team tested several methods to prepare shell waste before applying flash joule heating, or FJH. In that process, a flash of electricity heats the material to more than 3,000 degrees Celsius for milliseconds. The rapid heat rearranges the carbon atoms into graphitic structures, including few-layer turbostratic graphene.

The study found the preparation stage made a major difference to the final result. The best method used a staged pretreatment, starting with indirect Joule heating at about 500 degrees Celsius for 5 minutes, followed by a short higher-temperature step.

That treatment removed impurities and converted the shells into char, a carbon-rich material that is much more conductive than raw peanut shells.

“That process is vital to remove the impurities and give us the best carbon-rich material to help ensure there are minimal defects in the final graphene and that it is indeed just a single layer of atoms,” Yeoh said.

“That's what you want and need to ensure that it has the best properties in terms of conducting electricity and heat.”

Researchers have tried turning peanut shells into graphene before, but this study points to the value of carefully controlling the precursor material to lift the quality of the graphene produced.

The researchers said the process still has limits. The graphene scored highly for quality, but it is usually made up of a few graphene layers stacked in a turbostratic arrangement. They also said it could take three to four years to scale the technique up for commercial use.

The work remains at the proof-of-concept stage, and the team plans to keep refining the process in the lab. The researchers also want to test the same preparation and heating method on other kinds of biomass.

“We are planning to also carry out experiments with other materials, such as coffee grounds, or banana peels, or anything else that can give us that good char to then turn into graphene,” Yeoh said.

“Considering how much organic material like that is available, our work demonstrates a good balance between the energy efficiency, the quality of graphene we end up with, and the economic viability of the whole process.”

The research was published in Chemical Engineering Journal Advances.

Shell Shocked! Scientists are Turning Peanut Shells Into High-Quality Futuristic Graphene

Science Daily

For a drug already in use, lecanemab has carried a basic question for years, how does it actually clear amyloid from the brain? Scientists in Belgium now say they have the clearest answer yet.

Researchers from VIB and KU Leuven reported that lecanemab, sold as Leqembi, depends on a specific part of the antibody called the Fc fragment to switch on microglia, the brain’s immune cells, so they can clear amyloid plaques. The team said the work is the first clear explanation of how this kind of anti-amyloid therapy functions in Alzheimer’s disease.

The findings were published in Nature Neuroscience.

Lecanemab is a monoclonal antibody treatment for Alzheimer’s disease that targets and removes harmful amyloid plaques while slowing cognitive decline. The new research focused on how that plaque-clearing process happens.

“Our study is the first to clearly demonstrate how this anti-amyloid antibody therapy works in Alzheimer’s disease. We show that the therapy’s efficacy relies on the antibody’s Fc fragment, which activates microglia to effectively clear amyloid plaques,” said Dr. Giulia Albertini, co-first author of the study.

“The Fc fragment works as an anchor that microglia latch onto when they are near plaques, as a consequence of which these cells are reprogrammed to clear plaques more efficiently.”

More than 55 million people worldwide live with Alzheimer’s disease, according to the researchers. The disease is driven by the buildup of amyloid plaques in the brain. These toxic protein clusters damage neurons and eventually lead to dementia.

Microglia naturally gather around these plaques, but they are typically unable to remove them effectively. Researchers have been developing treatments aimed at restoring that immune function.

Lecanemab is one of the therapies designed to target amyloid-beta plaques and slow disease progression, and it has already received FDA approval. But the researchers said side effects have limited its overall benefit, and until now its exact mode of action remained unclear.

Antibodies have two main parts. One part binds to a target such as amyloid plaques. The other, the Fc fragment, signals the immune system.

Earlier research had suggested microglia were involved in clearing plaques, but direct proof linking their activity to lecanemab’s effectiveness was missing. Some scientists had also proposed that plaque removal could happen without the Fc fragment.

The team led by Professor Bart De Strooper found that the fragment is essential. Microglia responded only when the Fc fragment was intact and functional. When the researchers removed it, the antibody no longer had any effect.

To test that, the researchers used a specially designed Alzheimer’s mouse model that included human microglial cells. They said that let them closely observe how lecanemab interacts with human immune cells and promotes plaque clearance.

“The fact that we used human microglia within a controlled experimental model was a major strength of our study. This allowed us to test the very antibodies used in patients and observe human-specific responses with unprecedented resolution,” said Magdalena Zielonka, co-first author.

The researchers then looked at how activated microglia remove amyloid plaques in that model. They identified key cellular processes involved in the cleanup, including phagocytosis and lysosomal activity. They said those processes were triggered only when the Fc fragment was present. Without it, the microglia stayed inactive.

Using single-cell and spatial transcriptomics, the team also identified a specific pattern of gene activity in microglia linked to effective plaque removal. That pattern included strong expression of the gene SPP1.

The researchers said they identified that pattern using NOVA-ST, a method developed by the Stein Aerts lab at VIB-KU Leuven.

The study, the researchers said, also points to possible new approaches for Alzheimer’s treatment. By identifying the exact microglial program involved in clearing plaques, the findings suggest future therapies could activate microglia directly instead of relying on antibodies.

“This opens doors to future therapies that may activate microglia without requiring antibodies. Understanding the importance of the Fc fragment helps guide the design of next-generation Alzheimer’s drugs,” said Professor Bart De Strooper.

The research was carried out at the VIB-KU Leuven Center for Brain & Disease Research and was supported by the European Research Council, Alzheimer’s Association USA, Research Foundation Flanders, Queen Elisabeth Medical Foundation for Neurosciences, Stichting Alzheimer Onderzoek, Fondation Recherche Alzheimer, KU Leuven, VIB, and UK Dementia Research Institute University College London.

Scientists Finally Crack How This Alzheimer’s Drug Clears the Brain

Smithsonian Magazine

A page historians thought was gone has turned up in a French museum archive, and it belongs to one of the most famous manuscripts in mathematics.

Researchers say a missing leaf from the Archimedes Palimpsest has been found at the Musée des Beaux-Arts in Blois, France. The rediscovered page was sitting in the museum’s archives, according to the French National Center for Scientific Research, or CNRS.

The Archimedes Palimpsest is a 177-page manuscript created in the tenth century C.E. It contains rare copies of treatises by Archimedes, the third-century B.C.E. mathematician, as well as writings by other authors.

Archimedes made major discoveries in mathematics, engineering and physics. In the sixth century C.E., Isidore of Miletus, the architect of the Hagia Sophia, compiled the first known collection of his treatises. Today, two of those treatises, The Method and Stomachion, survive only through the Archimedes Palimpsest, which was created by an unknown scribe in Constantinople.

The manuscript later ended up in a monastery, where 13th-century monks reused the parchment as a prayer book. They decided to “wash, scrub and overwrite” the pages, writes Artnet’s Richard Whiddington.

“This practice of recycling was common at the time for such animal-skin writing materials, which were extremely costly,” according to a CNRS statement.

In 1906, a historian photographed every page of the manuscript. But three leaves later went missing. The manuscript was sold for $2 million at a Christie’s auction in 1998 and was later displayed at the Walters Art Museum in Baltimore.

William Noel, a curator of ancient manuscripts at the Walters Art Museum, described the manuscript’s significance in 2007.

“This book never ceases to give up its secrets,” Noel told Smithsonian magazine’s Mary K. Miller. “It’s like working with a great mind; you’re made to think of things in new ways, from the nuts and bolts of medieval history to the roots of calculus and physics.”

The newly identified page is leaf 123. Researchers said it matched the 1906 photographs.

The find began with a conversation between colleagues. Victor Gysembergh, a historian at CNRS, told Agence France-Presse that he and his co-workers had been talking about how French kings used to keep precious parts of their libraries in Blois.

Gysembergh then suggested checking for a palimpsest there.

“Hey, let’s see if there’s a palimpsest in Blois,” he told AFP. “It was very unexpected to stumble upon a Greek manuscript. And even more so to find a tenth-century scientific treatise!”

According to CNRS, one side of the leaf still preserves part of Archimedes’ work.

“On one of its two sides, a text of prayers partially covers geometric diagrams and a passage from the treatise On the Sphere and the Cylinder, Book I, Propositions 39 to 41, much of which remains largely legible,” the statement said.

The other side presents a tougher problem.

“The other side is covered by an illumination added in the 20th century, depicting the prophet Daniel surrounded by two lions, beneath which the ancient text remains to this day inaccessible using conventional methods of examination,” according to the CNRS statement.

The researchers published their findings in the German Journal of Papyrology and Epigraphy. They hope to use X-rays and multispectral imaging to read the hidden text. The same technique was used to reveal passages from the manuscript in the early 2000s.

Abigail Quandt, the senior conservator of manuscripts and rare books at the Walters Art Museum, described that earlier conservation work in a 2011 statement.

“I documented everything and saved all of the tiny pieces from the book, including paint chips, parchment fragments and thread, and put them into sleeves so we knew what pages they came from,” Quandt said. “I stabilized the flaking ink on the parchment using a gelatin solution, made innumerable repairs with Japanese paper and reattached separated folios.”

Officials do not yet know if the rediscovered leaf will be reunited with the rest of the manuscript in Baltimore.

Photo by © Blois, Musée des Beaux-Arts, Inv. 73.7.52. Photography IRHT-CNRS

Researchers Rediscovered a Lost Archimedes Manuscript Leaf In the French Museum Archives

For years, this kind of cancer drug looked like a dead end. It fired up the immune system, sure, but it also caused enough damage to make doctors hesitate.

Now, a small trial is flipping that story on its head.

Scientists testing a redesigned version of a long-studied therapy say it shrank tumors in half of the patients involved, and in two cases, wiped the cancer out completely. Even more surprising, the treatment was injected into just one tumor, yet tumors elsewhere in the body also disappeared.

That kind of ripple effect is rare.

"Seeing these significant shrinkages and even complete remission in such a small subset of patients is quite remarkable," says Juan Osorio, a visiting assistant professor in Jeffrey Ravetch’s lab at Rockefeller University and a medical oncologist at Memorial Sloan Kettering Cancer Center.

The drug, known as 2141-V11, belongs to a class called CD40 agonist antibodies. Scientists have been studying them for more than 20 years. Early lab work showed promise. These drugs can push the immune system into attack mode, helping it recognize and destroy cancer cells.

But when researchers tried them in people, the results were underwhelming. Tumor responses were limited, and side effects were hard to ignore. Patients developed widespread inflammation, dangerously low platelet counts, and liver damage. And that was at relatively low doses.

So Ravetch and his team took a different approach.

Back in 2018, they re-engineered the antibody itself. The goal was simple: make it better at activating the immune system while dialing down the collateral damage. Using specially designed mice that mimic human immune responses, they tested a version that binds more tightly to CD40 receptors and interacts more effectively with another immune component known as an Fc receptor.

In lab tests, the redesigned drug was about 10 times more potent at triggering an immune response against tumors.

But the real shift came in how they delivered it.

Traditionally, these drugs were given through an intravenous drip, spreading throughout the body. The problem is CD40 receptors are everywhere, not just on tumors. So healthy cells would soak up the drug too, leading to toxic side effects.

Instead, the team injected the therapy directly into a tumor.

"When we did that, we saw only mild toxicity," Ravetch says.

That decision set the stage for the first human trial.

The phase 1 study included 12 patients with advanced cancers, including melanoma, breast cancer, and kidney cancer. These were metastatic cases, meaning the disease had already spread.

Six of those patients saw their tumors shrink. Two experienced complete remission.

What caught researchers off guard wasn’t just the response rate. It was where the response showed up.

"This effect -- where you inject locally but see a systemic response -- that's not something seen very often in any clinical treatment," Ravetch notes. "It's another very dramatic and unexpected result from our trial."

In one case, a patient with melanoma had dozens of tumors on her leg and foot. Doctors injected just one tumor in her thigh.

"The melanoma patient had dozens of metastatic tumors on her leg and foot, and we injected just one tumor up on her thigh," Ravetch says. "After multiple injections of that one tumor, all the other tumors disappeared."

A similar outcome played out in a patient with metastatic breast cancer.

"The same thing happened in the patient with metastatic breast cancer, who also had tumors in her skin, liver, and lung. And even though we only injected the skin tumor, we saw all the tumors disappear."

To understand why, researchers looked closely at treated tumors.

What they found looked less like cancer and more like an immune training ground.

"We were quite surprised to see that the tumors became full of immune cells -- including different types of dendritic cells, T cells, and mature B cells -- that formed aggregates resembling something like a lymph node," Osorio says. "The drug creates an immune microenvironment within the tumor, and essentially replaces the tumor with these tertiary lymphoid structures."

These formations, called tertiary lymphoid structures, are often linked to stronger responses to immunotherapy. They act like mini command centres, helping the immune system organize and coordinate its attack.

What’s more, these structures showed up not just in the injected tumors, but in others throughout the body.

"Once the immune system identifies the cancer cells, immune cells migrate to the non-injected tumor sites," Osorio explains.

In other words, the initial injection seems to teach the immune system what to look for. After that, it takes over.

The trial was small and designed mainly to test safety, not to prove effectiveness. But the early signals were strong enough to push the research forward.

Larger trials are already underway, involving nearly 200 patients across phase 1 and phase 2 studies. Researchers are testing the therapy against several hard-to-treat cancers, including bladder cancer, prostate cancer, and glioblastoma.

Now the focus is shifting to a familiar challenge in cancer care: figuring out who benefits most.

The two patients who experienced complete remission had one thing in common. At the start of the trial, their immune systems already showed high levels of T cell clonality, meaning their T cells were primed to recognize specific targets.

"This suggests there are some requirements from the immune system in order for this drug to work, and we're in the process of dissecting these characteristics in more granular detail in these larger studies."

That question matters because immunotherapy doesn’t work for everyone. In many cases, only about a quarter to a third of patients respond.

"As a general rule, only 25 to 30% of patients will respond to immunotherapy, so the biggest challenge in the field is to try to determine which patients will benefit from it. What are the indicators or predictors of response? And how can we convert non-responders into responders?"

For now, the results offer something researchers have been chasing for years: a way to activate the immune system against cancer without setting off alarms everywhere else in the body.

And it all starts with a single shot.

Photo by AI/Sciencedaily.com

Scientists Inject One Tumor and Watch Cancer Vanish Across the Body

Cleaner air can sound like a slow, distant goal. But a new report says some cities have already made big gains.

A report from breathecities.org examining the air quality of 100 global cities found 19 had substantially improved since 2010. Nine of those 19 were in China and Hong Kong. The rest were in Europe, and included both large and small cities.

In the United States, San Francisco reduced both health-harming fine particulate matter, known as PM2.5, and airway-aggravating nitrogen dioxide, or NO2.

The report said there is no minimum safe level of PM2.5, which refers to particulate matter with a diameter of 2.5 micrometers. It has been linked to many different diseases, from asthma to Alzheimer’s, throughout a human life.

“This report shows that cities can achieve what was once thought impossible: cutting toxic air pollution by 20-45% in a little over a decade,” said Cecilia Vaca Jones, recently-appointed executive director of Breathe Cities, one of the organizations behind the report.

“This isn’t just happening in one corner of the world; from Warsaw to Bangkok, cities are proving that we have the tools to solve this crisis right now.”

The report said the 19 cities used different combinations of measures. Those included replacing internal combustion engine vehicles with electric ones, adding more bike lanes in crowded European cities, and placing restrictions on woodburning stoves and fossil fuel power plants within city limits.

Beijing and Warsaw recorded the biggest reductions in PM2.5, at more than 45 percent. Amsterdam and Rotterdam posted the biggest improvements in nitrogen dioxide, also above 40 percent.

San Francisco reduced both pollutants by 20 percent.

The report found PM2.5 was more often reduced in European cities, which have focused more on switching electricity sources to clean energy. Chinese and other Asian cities had greater reductions in NO2 because of a stronger focus on replacing internal combustion engine cars with electric vehicles.

The report examined 100 global cities and found 19 had substantially improved since 2010.

New Report Finds 19 Global Cities Cut Toxic Air Pollution Since 2010

Greater Good Science Center

For many grandparents, time with grandchildren is a joy. A new study says it may also be linked to better cognitive health, especially for grandmothers.

Researchers used data from almost 10,000 grandparents in the English Longitudinal Study of Ageing who did not live with their grandchildren. Across three points over six years, the grandparents were asked if they had looked after their grandchildren without the child’s parents present during the prior two years.

Those who had provided care also reported how often they did it, in what circumstances, including school holidays, weekends, weekdays or throughout the year, and what kinds of activities they did. Those activities included caring for a grandchild when ill, play or leisure activities, and picking up or dropping them off at school.

At each time point, the grandparents also completed cognitive testing. That included a verbal fluency test, measuring how many animals they could name in one minute, and an episodic memory test, measuring how many words they could recall from a list immediately after hearing it and again after a five-minute delay.

The researchers compared caregiving and non-caregiving grandparents on cognition. After accounting for other differences that could influence caregiving status or cognition, including age, number of children and grandchildren, education, physical limitations or depression, they found that caregiving grandparents had greater cognitive strength at all three assessment points than matched non-caregiving grandparents.

Lead researcher Flavia Chereches of Tilburg University said the result fits with broader research on grandparenting and healthy aging.

“We know that staying active as we get older is good, by moving our bodies and by engaging in cognitive-stimulating activities,” she says. “Grandchild care can offer older adults opportunities for such activities.”

Chereches said happiness may also be part of the picture. While she and her team could not assess how much grandparents enjoyed caring for their grandchildren from the available data, she said other studies have found that positive emotion and better cognition are linked. Caring for a grandchild can also give grandparents a sense of meaning and purpose, which she said are known to help people age well.

“Research shows that having a sense of meaning and purpose is linked to better cognitive and overall health. If grandparents perceive caregiving as meaningful and fulfilling, that may help explain some of the benefits,” she says.

The study also looked closely at the type and frequency of caregiving. Chereches found that neither appeared to make much difference to the outcome. Any amount or type of caregiving was tied to better cognition at a given time.

But when the researchers looked at cognitive decline over time, they found a gender difference. Only grandmothers who provided care were protected in comparison to other grandparents. Grandfathers were not.

Chereches said she was not sure why, but said it could reflect differences in the way grandmothers and grandfathers care for grandchildren.

“Past research suggests that grandmothers often coordinate caregiving, making plans for how caregiving would look, while also performing more hands-on care, for example, cooking for the grandchild,” she says. “Grandfathers often take on a more supportive and recreational role.”

She said it is also possible that some grandfathers see caregiving as more of an obligation than a choice. It may be more stressful for them, or may interfere with other things they would prefer to do.

“What feels manageable and meaningful for one person may feel overwhelming for another,” says Chereches. “When caregiving becomes more of a source of strain rather than fulfillment, we would not expect positive effects,” she adds.

Chereches said no grandparent should feel badly if caring for a grandchild is not for them. She described caregiving as a complex task and said some people benefit more than others. Some grandparents may live far from their grandchildren, making it nearly impossible to help regularly. Others may simply prefer to spend their time in other ways.

Still, she said the results point to a possible benefit for grandparents who choose to stay involved. Along with possible gains for cognition, caregiving can also provide more social connection and physical activity.

“For grandparents who enjoy providing care, staying involved with grandchildren may be a meaningful and engaging way to remain active in later life,” says Chereches.

Caring For Grandchildren May Help Keep Your Brain Healthy, Says a New Study

Euro News

Europe’s tourist hotspots have spent months putting up barriers. Copenhagen tried handing out perks instead, and now other cities are taking notes.

The Danish capital launched CopenPay in 2024, rewarding tourists who show responsible and conscious behaviour. The aim is to show travellers that climate actions “can be much easier than they think,” while promoting sustainable tourism.

Under the program, travellers can get free bike rentals, boat tours and lunches if they help in communal gardens, collect litter and use public transport.

That approach has drawn attention from other destinations including Berlin, Helsinki and Bremen.

“Since launching CopenPay last summer, we’ve been met by an enormous interest from cities and tourist boards from Europe, Asia and North America, all wanting to know more about CopenPay and our learnings,” said Søren Tegen Petersen, CEO of Wonderful Copenhagen, to EuroNews.

“So far, we have shared insights on CopenPay with more than 100 interested parties.”

Bremen is the latest city to say it will launch its own version. The German city announced BremenPay, due to start in May 2026, as a tourism initiative rewarding sustainable travel choices.

The scheme would cover activities including walking, arriving by train, cycling, boat hires, extending a stay in Bremen and shopping consciously from second-hand shops and local, artisinal boutiques.

Travellers who provide proof of those activities, such as a photo or ticket, could receive rewards including free city tours, coffee and reduced admission fees to tourist attractions.

Bremen already has a related campaign with Deutsche Bahn. Overnight guests arriving by train receive surprise goodie bags with small gifts and vouchers from local tourism businesses.

“The campaign was very well received by our visitors and has encouraged us to further expand the concept, strengthening Bremen as a sustainable destination,” said Oliver Rau, managing director of Bremen Marketing and Tourism, Wirtschaftsförderung Bremen GmbH. “For 2026, we are planning an even larger initiative.”

Berlin is also considering a similar program and could begin pilot testing this year. The proposed model could reward travellers who arrive by train, stay longer, eat plant-based meals and take part in eco-friendly activities.

Possible perks include museum entry fee discounts, free food and complimentary bicycle rentals.

The city expects the program could help narrow the gap between tourists who want to act more responsibly and their actual behaviour. Berlin has suggested it would use mobile apps and points-based systems to manage rewards and engagement, alongside partnerships with local businesses.

Helsinki is also looking at a version of the idea, with a likely focus on regenerative tourism and Baltic Sea restoration projects in collaboration with other Baltic and Nordic destinations.

Its scheme would also encourage tourists to use public transport and cycle, with rewards such as free meals and discounted tours.

Elsewhere, some Alpine ski destinations are already using discounts to push lower-emissions travel. Via Lattea in Italy and Les Gets-Morzine in France are cutting up to 25 percent off ski passes this year for visitors who arrive by rail.

Rewarding responsible behaviour is not new. London has run similar local schemes for years. In July, during Plastic Free July, visitors and residents have been rewarded with a free drink for taking part in cleanups.

In Switzerland, travellers who explore the country by public transport can get free entrance to more than 500 museums with a Swiss Travel Pass, as well as up to 50 percent off most mountain railways.

Wild Sweden, an award-winning holiday company, also offers spa access and a free meal at Hotel Savoy in Lulea to visitors who arrive in Swedish Lapland by rail for their Northern Lights and wildlife holiday.

Last spring, Normandy launched a low-carbon tariff offering a discount of at least 10 percent on admission to 90 attractions and cultural sites. The offer applies to visitors arriving in the northern French region by bus, train or cycle, and can be used at castles, museums, monuments and parks, as well as for bike rentals, canoeing and escape rooms.

Download the world's only news app designed to spread joy and happiness.

What's Good Now!